Objective: The antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAVs) are multisystem diseases of the small blood vessels. Patients experience irreversible damage and psychological effects from AAV and its treatment. An international collaboration was created to investigate the impact of AAV on health-related quality of life (HRQoL), and develop a disease-specific patient-reported outcome measure to assess outcomes of importance to patients. Methods: Patients with AAV from the UK, USA, and Canada were interviewed to identify salient aspects of HRQoL affected by AAV. The study was overseen by a steering committee including four patient research partners. Purposive sampling of interviewees ensured representation of a range of disease manifestations and demographics. Inductive analysis was used to identify themes of importance to patients; these were further confirmed by a free-listing exercise in the US. Individual themes were recast into candidate items, which were scrutinized by patients, piloted through cognitive interviews and received a linguistic and translatability evaluation. Results: Fifty interviews, conducted to saturation, with patients from the UK, USA, and Canada, identified 55 individual themes of interest within seven broad domains: general health perceptions, impact on function, psychological perceptions, social perceptions, social contact, social role, and symptoms. Individual themes were constructed into >100 candidate questionnaire items, which were then reduced and refined to 35 candidate items. Conclusion: This is the largest international qualitative analysis of HRQoL in AAV to date, and the results have underpinned the development of 35 candidate items for a disease-specific, patient-reported outcome questionnaire. Keywords: ANCA-associated vasculitis, quality of life, patient-reported outcomes, granulomatosis with polyangiitis, microscopic polyangiitis, eosinophilic granulomatosis with polyangiitis
Introduction
Granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA) are organ-and life-threatening multisystem diseases of small arteries, known as the antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAVs). 1 Patients present with inflammation in multiple body areas, including the lungs, ear, nose, kidneys, joints, and nerves, 2 with fevers, weight loss, and fatigue. 3 Treatment is with glucocorticoids and other immunosuppressants. 4 A third of patients will have irreversible damage at diagnosis,
To guage the efficacy of treatments within RCTs, validated measurement of both physician-and patient-focused outcomes is key. 11, 26 The Outcome Measurement in Rheumatology (OMER-ACT) Vasculitis Working Group has consistently highlighted the need for a disease-specific patient-reported outcome (PRO) measure for patients with AAV, 25, 27 due to concern that the generic Medical Outcomes Short Form-36 (SF-36) may not capture all themes of importance. Since OMERACT 2012, 27, 28 an international collaboration (the UK, the USA, and Canada) has been developing an AAV disease-specific PRO measure, in line with the US Food and Drug Administration (FDA) guidelines for the development of PROs. 29 The development of a new PRO instrument involves three distinct stages with patient involvement at each step: 1) item generation and piloting, 2) item reduction and scale generation, and 3) testing reliability and validity. This paper describes the themes of importance in HRQoL in relation to AAV, identified through in-depth qualitative analysis in three countries in order to produce candidate questionnaire items for a new disease-specific PRO for AAV.
Methods
The study steering committee included members from the UK, USA, and Canada: four patient partners; medical sociologists with extensive experience in PROM development, testing, and application; qualitative researchers; and clinical researchers with an interest in vasculitis. An initial conceptual framework was developed, through literature review and steering committee input, to explore domains of interest, and this framework evolved during the study.
A core qualitative working group (CQWG), comprising researchers from the three countries, performed the qualitative analysis, developed a collaborative code book of themes, and produced and refined candidate items. The steering committee gave critical feedback throughout on developing themes and items and the project received critical scrutiny at three successive Vasculitis Workshop sessions at Outcome Measures in Rheumatology (OMERACT) conferences. 27, 28 Patient study sample
Patients diagnosed with AAV were recruited from three rheumatology centers in the UK, USA, and Canada. Inclusion criteria were age ≥18, ability to give informed consent, and a clinically verified diagnosis of GPA, MPA, or EGPA. Patients were purposively sampled to assure adequate representation of all three diseases, chronicity of disease, different age ranges, sex, and organ involvement. Study approvals were given by the NHS Research Committee South West-Central Bristol, the University of Pennsylvania Office of Regulatory Affairs, and the Ottawa Hospital's Research Ethics Board. All patients provided written informed consent.
In-depth interviews
Exploratory semi-structured patient interviews were conducted to identify the range of salient aspects of HRQoL affected by AAV and its treatment. An interview guide of prompts and cues was developed by the steering committee. Interviews were performed by a qualitative researcher in the US (KK) and two clinical research fellows trained in qualitative interview techniques in the UK (JCR) and Canada (NM).
Analysis
Interviews were recorded and transcribed, anonymized, and systematically analyzed using a modified framework method. [30] [31] [32] Coding was carried out using both an inductive (codes emerged during analysis) and deductive (codes anticipated) approach, 33 with NVivo computer software used to index transcripts. 34 Interviews continued until no new substantive themes arose indicating data saturation. 35 The CQWG defined the themes of interest, produced a common thematic framework, and ensured uniformity of coding across sites. A proportion of transcripts from each site was double coded, to ensure common approaches.
Candidate item development
Members of the CQWG recast themes as candidate items, using patients' descriptions throughout. Items were amended, and sometimes deleted by the CQWG, to reduce ambiguity and duplication. Piloting and further item amendment was conducted following feedback from steering committee patient partners. US participants were invited to participate in a free-listing activity, a semi-structured interview technique in which participants are given a question or statement and asked to identify words they associate with that phrase. 36 This method uncovers how groups of people with shared experiences create, associate, and categorize topics. 36, 37 The following questions were asked: "Which words would you use to describe your symptoms when your vasculitis: 1) first started; 2) is under control; and 3) is starting to flare?" Patient partners on the study team performed pile-sorting of the responses independently, with disagreement resolved through consensus. Following free-listing and pile-sorting, the Smith's Salience Index (SSI) 38, 39 was used to identify the most salient terms. SSI scores were calculated using ARTHROPAC software. The identified salient terms were contrasted across interview themes to provide additional lens of validation for candidate item development.
Patient refinement
Three rounds of patient cognitive interviews were completed, in order to check understanding and interpretation of the candidate items. 40, 41 This was an iterative process, with items refined or rejected by the CQWG between each round.
In parallel, a readability and translatability assessment was completed in collaboration with a specialist UK company (Pharmaquest -translation and linguistic validation company for PROs). 42 A breakout session was also held at the Vasculitis Workshop at OMERACT 2014, which sought feedback about 1) inclusion of contextual factors within the PRO and 2) attribution within the stem (or lead in sentence), to vasculitis and/or its treatment. All proposed item changes were tested by further cognitive interviews and steering committee review.
Results
Fifty participants, 24 men and 26 women, were interviewed in the UK, USA, and Canada. Participants' characteristics are shown in Table 1 . Interview transcripts were analyzed, identifying 55 individual themes of interest, grouped into seven domains (definitions of individual themes within the codebook in Table S1 ). The domains identified were general health perceptions, impact on function, psychological perceptions, social perceptions, social contact, social roles, and symptoms (Box 1 shows domain structure and individual themes). The saturation table of emergent themes is shown in Table S2 .
General health perceptions
Eighty-six percent of patients used descriptions of how their general sense of self and wellness had been affected by developing AAV. Concerns about the future and difficulties making long-term plans were prominent, as was a sense of vulnerability in one's own body. 
Impact on function
Ninety percent of participants described difficulties with reduced levels of physical function, over 80% had a reduction in mobility, and 20% described difficulties in washing and dressing. These impairments led to frustration and impacted finances and work (82%), the ability to perform household tasks (72%), taking part in hobbies and interests (46%), and restricted travel (76%).
"Weakness, inability to walk, to use my arms, to bathe, to do anything -I just laid in bed". [82-year-old male with MPA] "TV was a no-no. I got a telephone with a light on it, because it [the deafness] was that bad… I felt very isolated and very stupid". [57-year-old male with GPA]
Psychological
Concerns about the future were highlighted in 86% of interviews with over 70% reporting experiencing fear, anxiety, or stress, and 50% describing depression or low mood. Anger or irritation was reported by almost 50%. Difficulties in making plans and the potential for premature death were described by patients of all ages.
"For the first year after I was diagnosed, I did nothing, apart from cope with me, my illness and trying to live as normal a life as possible". 
Social perceptions
Participants were aware of the visibility of the condition, and its treatment side-effects, particularly in relation to glucocorticoids; these issues were discussed in 64% of interviews. A lack of empathy from others was reported by around 60% of interviewees, as was being the source of worry to others. (14) m. Numbness and nerve symptoms (12) e. Sex and intimate relationships (7) n. Joint symptoms (31) 
Social role
Eighty-two percent of participants discussed their occupation or finances, specifically stemming from difficulties with concentration and fatigue. Roles beyond work were also discussed, within the family (70%), and changes to role and status when having to rely on others for help (64%).
"When I was getting sick in the beginning I gave up my position as the executive director of the organization and I moved into a position with less responsibility". [52-year-old female with GPA] "It was hard on my son as well, so he started goofing off in school. I felt like I wasn't a good mom, I wasn't a good wife, and I was isolated". [51-year old female with EGPA]
Symptoms
All of the patients described symptoms due to disease and treatment in depth. Nineteen different sets of symptoms were identified, most frequently fatigue (88%), cardiorespiratory symptoms (76%), issues related to body weight (74%), and upper respiratory tract symptoms (70%). A full list of symptoms is given in Box 1, with quotes in Box 2.
Free-listing and pile-sorting items of importance to patients with AAV All 17 US patients interviewed were invited to free-list terms they associated with the onset, remission, and flaring of their AAV (Figure 1 ). The most salient themes at onset were pain and discomfort (SSI=0.37), nasal and sinus problems (SSI=0.32), and fatigue and energy levels (SSI=0.27). Emotional effects were within the top three during flare (SSI=0.28) and remission (SSI=0.27). Themes identified were compared with the individual themes of interest and domains from the in-depth patient interviews and no new themes were identified (Box 1 for overview and Table S1 for detailed descriptions).
Candidate item development
Fifty-five individual themes were identified from the qualitative work (Box 1), and these were recast into an initial list of 105 candidate items by members of the CQWG. Patient descriptions informed the design of the candidate questionnaire items and response options, resulting in different sections. Patients described the overall severity of their symptoms, rather than the frequency; pain was usually described in relation to specific body areas, such as joints or muscles; and ability to function was described in terms of the amount of difficulty with completing a specific task. The candidate items were scrutinized for duplication and ambiguity of items, reducing the item pool to 42 items. Patients made it clear that it was difficult to tease apart symptoms caused by AAV versus its treatment, so both were included within the stem of the question. Items related to contextual factors (eg, support and self-efficacy -Box 1 and Table S1) were not included within the PRO itself, after discussion at an OMERACT 2014 breakout session with patient participants. 28 Three rounds of cognitive interviews were conducted in the UK and USA, using the 42-item version of the questionnaire, with amendments after each round. Word changes were suggested by patients, for example, clarification of the word essential in relation to activities, and change to the period of recall from 7 days to 4 weeks. All participants reported that the questionnaire captured content relevant to them. Seven items were rejected because of ambiguity, repetition, or being contextual factors. Following the translatability assessment (Box S1), minor changes were made to a few items, and these revisions were piloted in the last round of interviews. The conceptual framework evolved in response to insights from the qualitative research, feedback from the steering committee, and breakout sessions at OMERACT, and the final version is shown in Figure 2 
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Robson et al differing disease manifestations, a wide demographic range, and three different countries. The item generation for a novel, disease-specific PRO measure is underpinned by this qualitative research, which should ensure that the final candidate items have good face validity within each country. Themes identified in previous quantitative studies are confirmed, for example, fatigue, 13 anxiety, and depression, 16 and the impact on everyday function and employment. 17, 43 Newer themes include difficulties in making plans, from short-term social engagements to life planning, previously reported in patients with systemic lupus erythematosus, rheumatoid arthritis, and GPA. 19, 44, 45 The strengths of this study include a high level of patient involvement, and ongoing critical review through OMER-ACT Workshops, which have helped to ensure that each stage was consistent with best practice. Patients were purposively sampled to include a range of disease features and demographics, including a high proportion of patients with recent active disease. This was to ensure a focus on themes (and then items), which would exhibit greatest change in the context of a RCT. A third of patients had longer-standing disease, and saturation of themes was also reached within this patient group. The high rate of relapsing disease may also be a reflection of the fact that patients with GPA, who have a higher rate of relapse, 46 were slightly over-represented compared with patients with MPA; this may be a potential bias of the sample. That only English-speaking participants were included is a limitation of this study. However, a translatability assessment was performed for the questionnaire items, to ensure that any future translation into a range of languages should be straightforward. 47 In addition, care was taken to develop items that were not overly culture-specific, for example, describing "difficulties with traveling far from home," rather than "going on holidays." Interviews were performed by clinical fellows in the UK and Canada, and this may have changed the way that patients described problems in relation to their disease or treatment. Training was, therefore,
Box 2 Patient descriptions of symptoms of ANCA-associated vasculitis and its treatment
Fatigue: "So with the severe flares, the fatigue is indescribable. Looking back, I don't know how I got up and went to work every day last year".
[30-year-old. F, GPA] Cognition/concentration: "You feel like you have the flu, sort of achy and really tired, your head is kind of fuzzy, it's hard to think and concentrate". [52-year-old. F, GPA] Issues related to body weight: "Taking too many prednisolone really made me eat a lot and gain weight". 58-year-old. M, EGPA. Sleep symptoms: "I wake up tired, just really tired. There doesn't seem to be any refreshing sleep, no matter how long I try and sleep for".
[53-year-old. F, EGPA] Temperature instability: "I'd have high fevers and night sweats, tremendous night sweats". 51-year-old. F, EGPA. Skin problems: "Your skin is so thin that it tears" 04.202. "I had a rash, and I couldn't get rid of it, breaking out down my arms and chest… it drove me crazy". 
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Robson et al be used to measure and compare HRQoL between patients with different chronic conditions, and population norms. A combined approach of using disease-specific and generic PRO measures may, therefore, be the optimum way of comprehensively measuring HRQoL in AAV.
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The 35-item candidate questionnaire will need to be shortened to reduce responder burden and optimize feasibility within RCTs. The next stage of development will involve a large-scale survey to facilitate further item reduction, and determine the underlying scale structure and measurement properties (reliability, validity, and responsiveness) of the final AAV-PRO instrument. provided by experienced social scientists, who also evaluated all interview transcripts.
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Patient impact of ANCA-associated vasculitis Perception that others (partner, family, friends) do or do not understand (how bad/ill/tired they feel). Can be coupled with reluctance to explain too much detail to others (thereby compounding the problem) or thinking that others do not believe them. May socialize more with others who have vasculitis -who understand c. Source of other people's worry
Supplementary materials
Perception that friends or family are anxious on their behalf -or are worried that they might become "a responsibility"/burden. Or might be contagious 5. Social contact a. Impact on social life Content relating to less energy for socializing, reduced social contact in person, improved social relationships, and social isolation (vulnerability, loss of confidence in social situations) b. Social activities and participation Unable to engage in social activities that the person wants to or was doing, before the illness struck, for example, sports and community participation including organized religion c. Adaptations to facilitate social life AAV-related difficulties (eg, mobility problems/sensory impairment/fatigue) mean that social occasions require pacing or special planning d. Quality of communication Impaired hearing/voice problems make communications difficult e. Sex and intimate relationships
Difficulties within relationships and with sex either because of AAV or its treatments 6. Social role a. Occupation or finances Worry concerned with their ability to do/or get back to doing, their job ("pull their weight"); worries about losing their job -because of effects of AAV on their ability to do their specific type of work, or any kind of work ("hold down a job"). Might include financial worries -if they were unable to continue in work (or to the same level). Loss of income -perhaps additional costs incurred, for example, house or transport adaptations, because of AAV. Could also include unpaid work b. Family and family planning Worry about the effect that their AAV is having on their family: changing roles (their increased dependency); how family will manage if their work is affected (reduced/lost) or if they die. Feeling like a burden on their family. Effects on decisions about family size. Increasing stress and conflict within family c. Dependency on others Needs help from others/partner to do certain tasks/go outside the home (may be contrasted with former role where others were more dependent on them) d. Role identity and status Unable to be helpful/useful to others (as in the past) -associated with a sense of letting others down as it relates to significant others, family, or work associates. Change in status at work or in society 7. Symptoms a. Fatigue Fatigue, exhaustion, or energy drain, which can be intermittent, sudden, or persistent/ constant. Has "normal" level of energy some (hours or days) of the time, then suddenly overcome with fatigue/tiredness/weakness. Or persistent lack of energy, fatigue/tiredness/ weakness over many days, weeks, or months b. Cognition and poor concentration
Difficulties with focusing on a topic for any length of time. Generally feels distracted or thoughts "drift off" "in a fog." Trouble making decisions and understanding others or situations c. Issues related to body weight Weight loss, gain, or distribution, causing concern -could be secondary to lost appetite or steroids Box S1 Translatability of the questionnaire
• The translatability of the questionnaire refers to whether items can be meaningfully translated into other languages in the future.
50
• First, a concept elaboration document is produced, which clarifies any ambiguities or nuances within the candidate items and instructions.
• For each item and instruction, concepts and wording are then checked to ensure equivalence between the original and target language, and whether they remain linguistically and culturally appropriate. A sample of different types of languages is tested.
• Arabic (Egypt), Finnish (Finland), German (Germany), Greek (Greece), Russian (Russia), Spanish (Argentina), and Xhosa (South Africa) were the languages tested in this study. • The questionnaire items were then refined to enable better cultural and linguistic equivalence across future translations, and thereby to improve the measure's performance when used in international studies.
• A translatability assessment does not go as far as conducting full-scale translation/back-translation process, with testing for validity in another language(s). This is for the future (once the number of questionnaire items has been finalized) and would require a full study for each language. However, the translatability assessment that was undertaken should ensure that future translations are more straightforward and will better facilitate equivalence. 1 1 1 1 1 0 1 1 1 1 1 1 1 0 1 1 1 1 0 0 1 0 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 43 b. Lack of 1 1 0 1 1 0 0 1 1 1 1 0 1 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 45 b. Personal mobility 0 1 0 1 0 1 1 1 1 1 1 0 1 1 1 1 1 1 1 0 0 1 0 1 1 1 1 1 1 1 1 1 0 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 41 c. Scope for travel 0 1 1 1 1 1 0 0 1 1 1 0 1 1 0 1 0  0 1 1 1 1 0 1 1 1 1 1 0 1 1 1 1 0 1 1 1 1 1 1 0 1 1 1 1 1 1 0 1 1 38 d. Household 1 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1 0 36 e. Treatment 1 1 1 0 1 1 0 1 1 1 1 1 0 0 1 1 1 1 1 0 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1 43 b. Fear, anxiety, stress 0 1 1 1 1 0 0 1 0 1 0 1 1 0 1 0 1 1 1 1 1 1 0 1 1 1 1 1 0 1 1 1 0 1 1 1 1 0 1 1 1 1 1 1 1 0 1 0 1 1 37 c. AAV 1 1 1 1 1 1 1 0 1 1 1 0 1 0 0 1 1 1 1 1 0 1 1 1 1 1 0 1 0 1 1 1 1 33 e. Information 1 1 1 1 1 0 1 1 1 1 1 1 0 1 1 1 1 0 0 1 0 1 1 1 1 0 0 1 0 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 0 1 0 0 1 1 0 1 1 0 1 1 1 1 0 1 1 1 1 1 0 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 1 41 b. Effects on family and family planning 0 1 1 1 0 1 1 1 0 1 1 1 0 1 0 0 1 1 0 1 1  1 1 1 1 0 1 1 1 1 1 1 1 0 1 1 0 0 0 0 1 1 1 0 1 0 1 1 1 1 35 c. Dependency on 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 1 1 1 1 1 0 1 1 0 1 1 0 1 0 1 0 1 1 1 1 1 1 0 1 1 1 1 1 0 1 1 1 1 1 1 0 1 1 1 1 1 1 1 0 0 0 1 0 1 1 1 38 k. Gastrointestinal The journal is included in PubMed. The manuscript management system is completely online and includes a very quick and fair peer-review system. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.
Dovepress

34
